Amino Acid Metabolism in Breast Cancer: Pathogenic Drivers and Therapeutic Opportunities
en-GBde-DEes-ESfr-FR

Amino Acid Metabolism in Breast Cancer: Pathogenic Drivers and Therapeutic Opportunities

04/07/2025 Frontiers Journals

The review introduces the molecular subtypes of breast cancer and outlines how altered amino acid metabolism supports tumor growth. It explores key amino acid pathways—including glutamine, serine, glycine, aspartate, arginine, and tryptophan—and their roles in energy production, redox homeostasis, biosynthesis, and immune modulation. It also highlights the involvement of specific transporters and enzymes, and discusses emerging clinical applications, such as metabolic imaging and personalized therapies based on metabolic dependencies.
Key points of the review include:
  1. Glutamine metabolism: Glutamine serves as both nitrogen and carbon sources for cancer cells. Enzymes like GLS1 and GLS2 are differentially expressed across subtypes. TNBC shows high glutamine dependency, making glutaminase a promising therapeutic target.
  2. Serine and glycine metabolism: Serine is essential for nucleotide synthesis and redox balance. Overexpression of PHGDH and PSAT1 is common in aggressive tumors like TNBC and HER2+, suggesting vulnerability to serine biosynthesis inhibition.
  3. Aspartate and asparagine metabolism: Aspartate is vital for cell proliferation and nucleotide synthesis. High ASNS expression supports survival under stress. Aspartate also shows promise as a diagnostic biomarker for early-stage breast cancer.
  4. Arginine metabolism: breast tumors suppress ASS1, making them reliant on external arginine. Arginine deprivation strategies, like ADI-PEG20 treatment, are effective especially in TNBC. Arginine metabolism also influences redox and epigenetic regulation.
  5. Tryptophan metabolism: IDO1 and TDO2 convert tryptophan into kynurenine, promoting immune escape. This pathway is especially active in TNBC. Inhibiting IDO1/TDO2 can reverse immunosuppression and reduce metastasis.
Amino acid metabolism is fundamentally linked to breast cancer subtype biology and therapeutic resistance. Different subtypes show distinct metabolic dependencies that can be exploited for targeted therapy. Transporters and metabolic enzymes represent promising drug targets, while imaging techniques and personalized strategies may enhance diagnostic accuracy and treatment effectiveness. Understanding and manipulating these metabolic networks could pave the way for more effective, precision-based interventions in breast cancer care. The work entitled “ Amino Acid Metabolism in Breast Cancer: Pathogenic Drivers and Therapeutic Opportunities ” was published on Protein & Cell (published on Feb. 20, 2025).
DOI:https://doi.org/10.1093/procel/pwaf011
Reference: Yawen Liu, Xiangyun Zong, Patricia Altea-Manzano, Jie Fu, Amino Acid Metabolism in Breast Cancer: Pathogenic Drivers and Therapeutic Opportunities, Protein & Cell, 2025; pwaf011, https://doi.org/10.1093/procel/pwaf011
Attached files
  • Image: This review illustrates amino acid metabolic reprogramming in breast cancer, highlighting its role in tumor progression and clinical applications, including diagnostic imaging, targeted therapies, dietary interventions, and combination treatments for personalized care.
04/07/2025 Frontiers Journals
Regions: Asia, China
Keywords: Science, Life Sciences, Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement